Tango Therapeutics Inc
Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant … Read more
Tango Therapeutics Inc (TNGX) - Total Assets
Latest total assets as of September 2025: $210.14 Million USD
Based on the latest financial reports, Tango Therapeutics Inc (TNGX) holds total assets worth $210.14 Million USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Tango Therapeutics Inc - Total Assets Trend (2019–2024)
This chart illustrates how Tango Therapeutics Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Tango Therapeutics Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Tango Therapeutics Inc's total assets of $210.14 Million consist of 84.2% current assets and 15.9% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 22.0% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2019–2024)
This chart illustrates how Tango Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Tango Therapeutics Inc's current assets represent 84.2% of total assets in 2024, an increase from 74.7% in 2019.
- Cash Position: Cash and equivalents constituted 22.0% of total assets in 2024, down from 41.1% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2019.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Tango Therapeutics Inc Competitors by Total Assets
Key competitors of Tango Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx SE
OTCGREY:ARGNF
|
USA | $7.18 Billion |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Exicure Inc
NASDAQ:XCUR
|
USA | $15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Tango Therapeutics Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Tango Therapeutics Inc generates 0.13x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Tango Therapeutics Inc is currently not profitable relative to its asset base.
Tango Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 8.88 | 8.00 | 4.73 |
| Quick Ratio | 8.88 | 8.00 | 4.73 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $145.34 Million | $ 263.23 Million | $ 152.72 Million |
Tango Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Tango Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 10.86 |
| Latest Market Cap to Assets Ratio | 4.82 |
| Asset Growth Rate (YoY) | -21.4% |
| Total Assets | $316.49 Million |
| Market Capitalization | $1.52 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Tango Therapeutics Inc's assets at a significant premium ( 4.82x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Tango Therapeutics Inc's assets decreased by 21.4% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Tango Therapeutics Inc (2019–2024)
The table below shows the annual total assets of Tango Therapeutics Inc from 2019 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $316.49 Million | -21.38% |
| 2023-12-31 | $402.57 Million | -7.77% |
| 2022-12-31 | $436.47 Million | -12.73% |
| 2021-12-31 | $500.15 Million | +141.33% |
| 2020-12-31 | $207.25 Million | +271.66% |
| 2019-12-31 | $55.76 Million | -- |